Objective: To develop evidence-based recommendations for the management of antiphospholipid syndrome (APS) in adults.
Introduction
Antiphospholipid syndrome (APS) is a systemic autoimmune disorder with a wide range of vascular and obstetric manifestations associated with thrombotic and inflammatory mechanisms orchestrated by antiphospholipid antibodies (aPL). Common APS clinical features include venous thromboembolism, stroke, recurrent early miscarriages, and late pregnancy losses (1).
According to current laboratory criteria for APS, aPL antibodies can be one of three types: lupus anticoagulant, anticardiolipin antibodies, or anti-beta2 glycoprotein I antibodies. Definite APS, fulfilling at least one clinical and one laboratory criteria of the updated Sapporo classification criteria, can occur in association with other autoimmune diseases, mainly systemic lupus erythematosus (SLE), or in its primary form (primary APS) (1, 2) . Rarely, a life-threatening form of multi-organ thrombosis, known as catastrophic APS (CAPS), can occur. The presence of aPL in asymptomatic individuals or patients with SLE does not confirm the diagnosis of APS but can be associated with increased risk of thrombosis or pregnancy morbidity, depending on aPL characteristics and co-existence of other risk factors (3, 4) . The aPL type, the presence of multiple (double or triple) versus single aPL type, their titer (moderate-high titer vs low), and the persistence of aPL positivity in repeated measurements, is defined as the 'aPL profile'. The aPL profile is an important factor determining the risk of thrombotic and obstetric events, and consequently the intensity of treatment (3, 4) .
Clinical practice in APS is highly variable, in part because it is a rare disorder, and because knowledge about its diagnosis/classification, clinical spectrum, and management is continuously advancing. There is a great heterogeneity among studies on the laboratory and clinical criteria used to define APS and the treatment approaches used over the past four decades. These factors make it often difficult to know the best approach to apply in daily practice. In addition, there is a 6 paucity of high-quality randomized controlled trials (RCTs) in APS because of the difficulties conducting adequately sized trials in an uncommon disease and using randomized designs among patients with often devastating clinical presentations. The objective of this project was to develop evidence-based recommendations for the prevention and management of adult APS that will help guide practice and improve quality of care and patient outcomes.
Methods
We followed the updated EULAR Standardised Operating Procedure (5) and used the Appraisal of Guidelines for Research & Evaluation II (AGREE II) tool (6) . The steering committee included the convenor (MGT), co-convenor (AT), methodologist (MMW), and two physicians responsible for the systematic literature reviews (both were EMEUNET members) (LA, ML).
The task force included members from 11 European countries: 12 specialists in rheumatology or internal medicine, 2 obstetricians (RF, LR), 2 physicians from vascular medicine/thrombosis centers (VP, DW), 1 healthcare professional (KH), and 2 patient representatives (FM, JK).
The convenor prepared the first task force meeting and the first set of research questions on four major topics: risk stratification and risk modification in asymptomatic aPL positive patients, primary and secondary thromboprophylaxis in APS, management of obstetric APS, and management of catastrophic APS. The research questions were discussed among the task force members, and a set of 31 research questions was formulated using the PICO format (P=population; I=intervention; C=comparator; O=outcomes) and voted according to the Delphi method at a meeting in December 2017.
The data sources for the systematic literature review (SLR) were PubMed, Embase, and the Cochrane Library, which were searched for relevant English-language published articles from 7 their inceptions through January 31, 2018. We included one RCT published after this date because of the importance of its reported safety results (TRAPS trial) (7) . Search terms were developed with the aid of an experienced librarian, who performed the searches. All titles and abstracts of retrieved articles were first reviewed independently by the two literature reviewers.
The full-text articles were then reviewed independently by three persons: one literature reviewer, convenor, and methodologist. The data abstraction was performed by the two literature reviewers according to a written protocol and supervised by the methodologist. Data abstraction was then independently double-checked by the convenor and methodologist. Each included article was graded for its methodological quality and assigned to the relevant PICO question by the convenor and methodologist. Data were tabulated and summarized by the methodologist in an evidence report that included summary of findings tables with pooled estimates of effect sizes for studies that directly addressed the population, intervention and comparator of PICO questions.
Based on this evidence, a first draft of recommendations on 12 topics was prepared by the convenor and co-convenor. The draft recommendations and evidence report were sent to all task force members for review prior to the second task force meeting.
The second task force meeting, held September 3, 2018, included the presentation of SLR results, discussions of the first draft of recommendations in four working groups, working group presentations of the edited draft for each topic, and discussion and voting of the text.
Incorporating additional discussions on wording changes, the final set of overarching principles and recommendations, including the level of evidence (LoE) and grade of recommendations 
Results
The SLR yielded 7534 articles and 15 hand search articles. After the titles and abstracts review, 670 articles were selected for full-text review. The full-text review yielded 249 articles for data abstraction; 61 were excluded and 188 articles were finally considered to be relevant. A detailed presentation of the results of the SLRs that informed the task force recommendations is published separately and should be reviewed together with this report (9) . Based on the SLR results and expert's opinion, 3 overarching principles and 12 recommendations were developed.
Overarching principles
A. Risk stratification: Identifying the presence of factors associated with high risk for thrombotic and obstetric events is critical in patient management. A major risk factor is the high-risk aPL profile, including any of the following: the presence of lupus anticoagulant as the aPL subtype most closely related to thrombosis, the presence of double (any combination of lupus anticoagulant, anticardiolipin antibodies or anti-beta2glycoprotein I antibodies) or triple (all three subtypes) aPL positivity, or the presence of persistently high aPL titers (4, 10) , as also shown by aPL-score (11) and GAPSS (12) . Definitions of medium-high aPL titers, and of high-risk and low-risk aPL profiles are included in Table 1 . Additional risk factors for clinical events are co-existence of other systemic autoimmune diseases, especially SLE, a previous history of thrombotic and/or obstetric APS, and the presence of traditional cardiovascular risk factors (3, 4, 10) .
B. General measures:
The guidelines for cardiovascular disease (CVD) prevention in the general population should be followed. Screening for and management of venous thrombosis risk factors is also recommended. Heparin at prophylactic dosage, preferably low molecular weight heparin (LMWH), should be used in high-risk situations such as surgery, prolonged immobilization, and the puerperium. Table 2 presents the LoE, GoR and LoA for each recommendation. For recommendations with B GoR, we used the statement "is recommended". For C and D grades, we mostly used the terms "may be considered" or "could be considered", with some exceptions according to experts' judgment about the importance of the intervention. Recommendations that are phrased as "is recommended" are those that the task force meant, based on the evidence and their experience, should be followed in almost all cases.
Recommendations
Primary thromboprophylaxis in aPL positive subjects 1 . In asymptomatic aPL carriers (not fulfilling any vascular or obstetric APS classification criteria) with a high-risk aPL profile with or without traditional risk factors, prophylactic treatment with low dose aspirin (LDA) (75-100 mg daily) is recommended.
Use of LDA for primary prophylaxis is supported by results of a meta-analysis of seven observational studies of 460 asymptomatic aPL carriers that found the risk of first thrombosis to be reduced by one-half in those who used LDA versus those not used LDA (14) . Most patients had high-risk aPL profiles, but few had traditional CVD risk factors. An association of similar magnitude was present in a smaller individual-patient meta-analysis derived from these studies (15) . Neither meta-analysis display worrisome variations as the directions were clear. Although evidence was largely from observational studies, the panel recommended the use of LDA for primary prophylaxis in asymptomatic aPL individuals with high risk profile given the likelihood of benefit and low risk of adverse events of this intervention. Treatment with LDA for patients with SLE and high-risk aPL profile is supported by a subanalysis of eight studies, mostly observational, in a meta-analysis (14) . In this analysis, risk of first thrombosis was reduced by almost one-half among patients treated with LDA versus patients not treated, without major bleeding events. In an individual-patient analysis, this association was independent of the use of hydroxychloroquine (HCQ), suggesting that LDA offers additional benefit in this patient group (15) . Patients with high-risk aPL profile comprised the majority (but not all) of patients in these studies. Although there was heterogeneity between the studies, the direction of effect was clear. Less evidence is available on the use of LDA in 11 patients with SLE and low-risk aPL profile, but pooled data from two cohort studies indicate that the use of LDA was also associated with a lower risk of thrombosis in this group (16, 17) . 3 . In non-pregnant women with a history of obstetric APS only (with or without SLE), prophylactic treatment with LDA after adequate risk/benefit evaluation is recommended.
The primary prevention of thrombosis with LDA in women with a history of obstetric APS without SLE was addressed in a meta-analysis including five observational studies (14) . The pooled odds ratio for first thrombosis associated with use of LDA was 0.25 (95% CI 0.10, 0.62).
Studies of women with SLE and prior obstetric APS are scarce, but the protective effect of LDA was supported by three retrospective studies that included a minority of patients with SLE (18) (19) (20) . The panel recommended the use of LDA in women with a history of obstetric APS only, according to their thrombosis/bleeding risk (aPL profile, coexistent traditional cardiovascular risk factors, intolerance/contraindication to aspirin).
Secondary thromboprophylaxis in APS
4. In patients with definite APS and first venous thrombosis: a. Treatment with VKA with a target INR 2-3 is recommended.
In patients with APS and first venous thrombosis, after an initial therapy with unfractionated heparin (UFH) or LMWH and bridging therapy of heparin plus VKA, treatment with VKA with a target INR 2-3 is recommended. Data from an RCT (21) reporting exclusively in patients with venous events, and pooled data from five studies that included a majority with venous events (21) (22) (23) (24) (25) , showed no additional benefit of target INR 3-4 vs INR 2-3. However, evidence is limited by the frequent failure to achieve the target INR in the high-intensity groups in the RCTs.
Data on bleeding were not reported for patients with venous thrombosis specifically. However, although not based on data from these studies, higher level of anticoagulation would be anticipated to have also a higher risk of bleeding.
b. Rivaroxaban should not be used in patients with triple aPL positivity due to the high risk of recurrent events. DOACs could be considered in patients not able to achieve a target INR despite good adherence to VKA or those with contraindications to VKA (e.g. allergy or intolerance to VKA).
Despite the broadening use of DOACs in secondary thrombosis prevention in the general population, there is limited evidence about their effectiveness and safety in APS. In a post-hoc analysis of patients with APS included in three RCTs of dabigatran versus warfarin (26) , and in one RCT of rivaroxaban vs warfarin in patients with venous thrombotic APS (27) , there were no differences in outcomes between treatment with DOACs and VKA for venous thrombosis, but the evidence is limited by small samples, underrepresentation of high-risk APS patients and short follow-up. A recent RCT of rivaroxaban vs warfarin in APS patients with triple aPL positivity was prematurely terminated due to an excess of thromboembolic events (mostly arterial) in the rivaroxaban arm (7) . Accordingly, rivaroxaban should not be used in patients with triple aPL positivity. The panel agreed that DOACs may be considered in patients with difficulty achieving a target INR 2-3 despite compliance with VKA or who have contraindications to VKA.
Switching from treatment with VKA to DOACs due to low adherence to VKA or INR monitoring should be avoided. The use of VKA over LDA is supported by data from observational studies that showed a lower likelihood of recurrent thrombosis among patients with APS and prior arterial thrombosis (mainly stroke) treated with VKA vs LDA alone (31, 32 ). An early study in older patients with strokes reported no difference in event recurrences between LDA and warfarin, but aPL were tested only once and were mainly of low titer in this study (33). These issues make it difficult to apply the latter results to patients of any age who fulfill the laboratory criteria for APS. However, these studies included a mixture of patients with either venous or arterial thrombosis, and a minority had arterial events. In one trial that provided data specifically on patients with arterial thrombosis, there was no difference in recurrences between those treated to a target INR 2-3 or INR 3-4 but without statistical significance (HR 3.1 (0.3 -30.0), although the sample was small and the achievement of target INR 3-4 was low (21) . Because of these limitations, the higher intensity INR approach is preferred by some centers. In decision-making, physicians should take into account the individual's risk of recurrent thrombosis and major bleeding, as well as patients' preferences after discussion. Alternatively, treatment with VKA with target INR 2-3 plus LDA is used by some experts, supported by limited data from one retrospective cohort study and one small RCT (36-37).
c. Rivaroxaban should not be used in patients with triple aPL positivity and arterial events.
Based on the current evidence, we do not recommend use of DOACs in patients with definite APS and arterial events, due to high risk of recurrent thrombosis.
According to the results of the TRAPS trial (7), rivaroxaban should not be used in triple aPL positive patients with APS. In addition, an ongoing trial of apixaban in APS (ASTRO-APS) (ClinicalTrials.gov Identifier: NCT02295475) was recently modified after evaluation of their initial data to exclude patients with arterial thrombosis. Based on these data and those from case series reporting arterial thrombosis recurrences in APS patients treated with DOACs, use of DOACs is not currently recommended in patients with definite APS and arterial events (38) .
Ongoing clinical trials will help to better define the role of DOACs in APS. 
Obstetric APS
8. In women with a high-risk aPL profile but no history of thrombosis or pregnancy complications (with or without SLE), treatment with LDA (75-100 mg/day) during pregnancy should be considered.
Data from one placebo-controlled RCT of LDA in six women with SLE (42) , and data from three low-quality studies (2 RCTs, 1 retrospective cohort) (43-45) of women without SLE found no difference in the prevalence of live births with use of LDA. However, these studies did not specifically include women with a high-risk aPL profile. The panel agreed that use of LDA should be considered in pregnant women with high-risk aPL profile due to risk of obstetric and thrombotic complications during pregnancy associated with high-risk aPL profile.
9. In women with a history of obstetric APS only (no prior thrombotic events), with or without SLE:
a. In women with a history of ≥3 recurrent spontaneous miscarriages <10th week of gestation, and in those with a history of fetal loss (≥10th week of gestation), combination treatment with LDA and heparin at prophylactic dosage during pregnancy is recommended.
Pooled data from one RCT including only patients with a history of first trimester losses (46) and eight supporting observational studies (47-54) that did not exclusively study women with early pregnancy losses indicated a higher likelihood of live births with combination treatment with LDA and heparin at prophylactic dosage versus LDA alone. Some experts believe that LDA alone can be also effective. For women with a history of fetal loss, combination treatment with LDA and heparin was associated with a higher likelihood of live birth compared to treatment with LDA alone. However, these studies included women with histories of both early and midpregnancy losses (48) (49) (50) (51) (52) . LDA should be preferably started prior to conception, and heparin (LMWH or unfractionated heparin) should be added as soon as pregnancy is confirmed. LMWH is preferred for practical reasons.
b. In women with a history of delivery < 34th week of gestation due to eclampsia or severe preeclampsia or due to recognised features of placental insufficiency, treatment with LDA or LDA and heparin at prophylactic dosage is recommended considering the individual's risk profile.
Data from two studies (1 RCT, 1 retrospective cohort) (55, 48) showed that the likelihood of live births did not differ between women treated with LDA plus heparin and those treated with LDA alone. Physicians should tailor their treatment approach to individual's risk assessment including aPL profile and other risk situations (e.g. presence of other cardiovascular risk factors or immobility). The 'non-criteria' obstetric APS manifestations included in our search were the presence of two recurrent spontaneous miscarriages <10th week of gestation, or delivery ≥34 weeks of gestation due to severe pre-eclampsia or eclampsia. Because studies combined several types of pregnancy losses without specifying on the proportion of 'non-criteria' APS and due to very limited evidence this recommendation is mainly based on expert opinion. Because of a potential higher risk for obstetric and/or thrombotic complications during pregnancy in women with a history of clinical 'non-criteria' obstetric APS, the panel agreed that treatment with LDA alone or in combination with heparin might be considered, based on individual's risk profile (aPL profile, concomitant SLE, prior live births history, and additional risk factors for pregnancy loss or thrombosis).
d. In women with obstetric APS treated with prophylactic dose heparin during pregnancy, continuation of heparin at prophylactic dose for 6 weeks after delivery should be considered to reduce the risk of maternal thrombosis.
No studies directly tested the efficacy of extending treatment with prophylactic heparin after delivery. The panel suggested that in women receiving prophylactic dose heparin during pregnancy, the same dosage of heparin should be continued for 6 weeks after delivery, due to an increased risk of thrombosis at puerperium.
In women with 'criteria' obstetric APS with recurrent pregnancy complications despite
combination treatment with LDA and heparin at prophylactic dosage, increase heparin dose to therapeutic dose, or addition of HCQ, or low dose prednisolone in the 1st trimester may be considered. Use of intravenous immunoglobulin might be considered in highly selected cases.
The most common practice if the combination of LDA and prophylactic dose heparin fails is to increase the dose of heparin to therapeutic dose, although no supporting evidence exists. Other treatment strategies may include the addition of HCQ or low prednisolone doses in the first trimester. Evidence directly supporting these treatment options is based on two small observational studies with limited representativeness (56, 57) . Use of intravenous immunoglobulin (IVIG) was not associated with a higher proportion of live births compared to conventional treatment in three small observational studies (58) (59) (60) that directly addressed this question, although confounding by indication may have occurred. Although the expectation of benefit is small, the panel agreed that IVIG might be considered in highly selected cases when other treatments have failed.
11. In women with a history of thrombotic APS, combination treatment of LDA and heparin at therapeutic dosage during pregnancy is recommended.
In observational studies, treatment with LDA and therapeutic dose heparin was associated with live births in 79% of pregnancies on average (52, (61) (62) (63) (64) . Because a prior history of thrombotic APS is associated with increased risk for future thrombotic or obstetric events (65), treatment with LDA and heparin at therapeutic dosage during pregnancy is recommended. Switching treatment from VKA to therapeutic-dose LMWH or UFH is recommended as soon as pregnancy is confirmed, ideally before the sixth week of gestation, due to the teratogenic effects of warfarin (66) .
Catastrophic APS 20 12. The most common precipitating factors for the development of CAPS are anticoagulation discontinuation among patients with prior diagnosis of APS, infections, and surgical procedures (67) . Early diagnosis and management of infections and minimization of discontinuation or lowintensity anticoagulation, especially perioperatively, is recommended (68) . Based on the recently published clinical practice guidelines for CAPS management, combination therapy with glucocorticoids, heparin and plasma exchange or IVIG is recommended over single agents as first-line treatment of patients with CAPS (69) . Concurrent treatment of precipitating factors is also recommended (e.g. infections, gangrene or malignancy. For refractory CAPS, B-cell depletion (e.g. rituximab) or complement inhibition (e.g. eculizumab) therapies may be considered based on data from case reports (69) .
Discussion
APS is a complex disorder and its management often involves collaboration among several medical specialties. The aim of these recommendations is to provide guidance to all health professionals involved in patients' care, inform patients and support their engagement in shared decision-making, and provide evidence to researchers, funders and policy makers. The task force included members from several professional groups covering different perspectives and involved also two patients who participated actively in both meetings.
The main challenge in developing recommendations for the management of adult APS was the low certainty of evidence. Many studies included patients with a mix of different clinical features and did not provide stratified data for arterial or venous thrombosis separately or for each of various types of obstetric APS. This resulted in only indirect evidence for many of the treatment decisions that were examined. Several meta-analyses also pooled studies of heterogeneous patient groups. A high risk of bias and of low power, mostly due to the rarity of the syndrome, 21 was also common in RCTs. Therefore, a significant number of recommendations necessarily relied more, or only, on low-quality evidence or expert's opinion. An important consideration for future research would be well-designed observational studies and RCTs of homogenous patient populations. These studies will hopefully increase the quality of evidence for the currently used treatments and answer questions about controversial issues and new potential therapies (Research agenda, table 3).
The cost and availability of suggested treatments is not a barrier to implementation of these recommendations, with the exception of IVIG. However, both treatments were recommended as first line treatment only in catastrophic APS that occurs in less than 1% of patients, while B-cell depletion and complement inhibitors may be considered in refractory cases of catastrophic APS.
Implementation into clinical practice can be facilitated by the dissemination of the recommendations using the online media, by presentations in national and international congresses, development of workshops in meetings of different specialties involved in APS management, or educational lectures for health care providers in referral hospitals.
Better understanding of pathophysiologic mechanisms of APS will help to identify new therapeutic targets, and a balance between anticoagulation and immunomodulatory drugs for different APS manifestations. In addition, studies that examine homogeneous patient groups can better evaluate the efficacy and safety of the currently available and new treatments. When sufficient new information will be available, an update of the current recommendations will take place. The task force members believe that these recommendations will help to improve the quality of care in patients with APS and foster future research by highlighting evidence gaps. High-risk aPL profile. The presence of lupus anticoagulant, or the presence of double (any combination of lupus anticoagulant, anticardiolipin antibodies or anti-beta2glycoprotein I antibodies) or triple (all three subtypes) aPL positivity, or the presence of persistently high aPL titers.
Low-risk aPL profile. Isolated anticardiolipin or anti-beta2glycoprotein I antibodies at lowmedium titers, particularly if transiently positive (3). A. Risk stratification in aPL positive individuals should include determination of the presence of a high-risk aPL profile (defined as any of the following: multiple aPL positivity, lupus anticoagulant or persistently high aPL titers), prior history of thrombotic and/or obstetric APS, co-existence of other systemic autoimmune diseases such as SLE, and the presence of traditional cardiovascular risk factors.
B. General measures for aPL positive individuals should include screening for and strict control of cardiovascular risk factors (smoking cessation; management of hypertension, dyslipidemia and diabetes, and regular physical activity) in all individuals and particularly those with a highrisk aPL profile, screening for and management of venous thrombosis risk factors, and use of low molecular weight heparin in high-risk situations such as surgery, hospitalization, prolonged immobilization and the puerperium. 
